Coulomb-kontrollierte Iontophorese von Carboplatin zur Behandlung des
Retinoblastoms am transgenetischen Mausmodell by Voigt, Monika
Aus der Klinik für Augenheilkunde 








Coulomb controlled Iontophoresis of Carboplatin in the treatment of the 
transgenic murine retinoblastoma 
(Coulomb-kontrollierte Iontophorese von Carboplatin 






Zur Erlangung des akademischen Grades  




























































Gutachter:  1. ............................................... 
  2. ............................................... 





Datum der Promotion: 10. 11. 2006   
1. INTRODUCTION           3 
1.1. Iontophoresis in Drug Delivery        3 
1.1.1. History           3 
1.1.2. Basis           6 
1.1.3. Theory           6 
1.1.4. Factors affecting iontophoretic transport       8 
1.1.5. Pathways           9 
1.1.6. Advantages         10 
1.1.7. Risks and disadvantages       11 
1.1.8. Units/Devices        12 
1.2. Retinoblastoma         15 
1.2.1. Cell and molecular biology of the retinoblastoma    15 
1.2.2. Diagnosis         17 
1.2.3. Classification of retinoblastoma      18 
1.2.4. Management of retinoblastoma      19 
2. AIM OF THE STUDY         22 
3. MATERIALS AND METHODS        24 
 3.1. Coulomb-Controlled Iontophoresis device     24 
 3.2. Retinoblastoma Model        25 
 3.3. Animals          27 
3.3.1. Rabbits         27 
3.3.2. Mice         27 
 3.4. Treatment Modalities        28 
3.4.1. Subconjunctival carboplatin injections in rabbit eyes   28 
3.4.2 CCI delivery of carboplatin in rabbit eyes     28 
3.4.3. Intravenous delivery of carboplatin in rabbit eyes    29 
3.4.4. Repetitive CCI treatments on rabbit eyes – safety study    29 
3.4.5. CCI treatment parameter evaluation on mice eye    29 
3.4.6 Repetitive CCI treatments in transgenic retinoblastoma mice  30 
3.5. Analyses Modalities         30 
3.5.1. Rabbit ocular tissue dissection and preparation     30 
3.5.2. Electrothermal atomic absorption spectroscopy (ET-AAS)  31 
3.5.3. Electroretinography – ERG      31 
3.5.4. Histopathologic evaluation of rabbits and mice eyes   32 
 1 
3.6. Statistical Analysis        33 
3.6.1. Pharmacokinetic study performed on rabbits    33 
3.6.2. Tumor control analysis on transgenic mice    33 
4. RESULTS           34 
4.1. Results of treatments performed on rabbits     34 
4.1.1. Pharmacokinetics of carboplatin in the rabbit    34 
4.1.2. ERG results on rabbit eyes after repetitive CCI application  39 
4.1.3. Histopathology of repetitively CCI treated rabbit eyes   41 
4.2. Results of treatments performed on transgenic mice    44 
4.2.1. Histopathology of repetitively CCI treated mice eyes   44 
4.2.2. Iontophoretic treatment of transgenic mice    44 
5. DISCUSSION          51 
6. SUMMARY          57 
7. GERMAN SHORTREPORT-KURZFASSUNG     59 
7.1. Einleitung         59 
7.2. Material und Methoden       64 
7.3. Ergebnisse         66 
7.4. Diskussion         69 
 
8. REFERENCES          72 
9. CURRICULUM VITAE         83 
10. ACKNOWLEDGEMENT        87 
 
 2 
9. CURRICULUM VITAE  
Monika Voigt  
DOB: 17.11.1970  
Place of Birth: Berlin  
Nationality: German  





„Mein Lebenslauf wird aus Datenschutzgründen in der elektronischen Version 
















































I would like to specially thank PD Dr. Dr. PETER RIECK and PROF. Dr. Dr. CHRISTIAN 
HARTMANN for having given me the unique oportunity of doing research in the field of 
opthalmology in such remarkable places like the Laboratoires du développement, vieillissement 
et pathologie de la rétine unité INSERM U-450, the Laboratoire de Recherches 
ophtalmologiques Hôpital Hôtel Dieu Unité INSERM U- 86, Paris France and the Bascom 
Palmer Eye Institute Miami, Florida. 
Through the long period of my research they were always of tremendous help, not only 
concerning the scientific advice but as well in the creation and guidance of my medical thesis. 
 
My research fellowship at the Laboratoires du développement, vieillissement et pathologie de la 
rétine unité INSERM U-450 and Laboratoire de Recherches ophtalmologiques Hôpital Hôtel 
Dieu Unité INSERM U-86, Paris France was the foundation-stone for my further scientific and 
clinical carrier. My work in Paris was marked by the exceptional help, support and cooperation 
of Dr. FRANCINE BEHAR-COHEN (MD, Ph.D) and Dr. YVES COURTOIS (Ph.D). 
Without their initiative my fellowship in the United States would have been unimaginable. 
 
Through the financial support by the DAAD my fellowship at the Bascom Palmer Eye Institute 
Miami, Florida could come to reality. 
 
My work at the Ophthalmic Biophysics Center (OBC) Bascom Palmer Eye Institute Miami, 
Florida was an extraordinary scientific, social and cultural experience thanks to JEAN-MARIE 
PAREL (Ph.D) and the whole team of the OBC. 
 
Finally I would like to pay my special regards to TIMOTHY G. MURRAY, M.D under whom I 
had the pleasure to work at the LABORATORY FOR OCULAR ONCOLOGY and who made 
the realization of this research project possible. 

































Eidesstattliche Erklärung  
 
Hiermit bescheinige ich, daß die Dissertation von mir selbst und ohne die 
(unzulässige) Hilfe Dritter verfaßt wurde, auch in Teilen keine Kopie anderer Arbeiten 
darstellt und die benutzten Hilfsmittel sowie die Literatur vollständig angegeben sind. 
 
        Monika Voigt 
 
 
Objective: Retinoblastoma is the most common intraocular malignancy in children. Recently, 
the management of retinoblastoma has evolved away from radical aggressive treatments such as 
enucleation and external beam radiation, towards more focal, conservative treatments or moderate, 
combined treatment modalities.  The aim of this study was to characterize the pharmacokinetics 
and toxicity of systemic versus focal subconjunctival and transscleral Coulomb controlled 
iontophoresis (CCI) of carboplatin administration in the rabbit eye. The next step was to 
evaluate the efficacy and the dose response of transcorneoscleral Coulomb controlled 
iontophoresis (CCI) of carboplatin in the treatment of murine transgenic hereditary 
retinoblastoma.  
Methods: Pharmacological distribution of carboplatin was examined in New Zealand White 
(NZW) rabbits following a single intravenous infusion of carboplatin (18.7mg/kg body 
weight), a single subconjunctival carboplatin injection (5.0mg/400µl), or a single application 
of carboplatin delivered with CCI at 5mA/cm2 for 20min treatment duration (14mg/ml 
carboplatin solution). Following each treatment, animals were euthanized and eyes were 
obtained at either 1, 2, 6 or 24hrs post treatment. Six animals per time point were treated to 
ensure statistical significance. Right eyes were treated, left eyes served as controls. Atomic 
absorption spectroscopy analysis was used to determine the carboplatin levels in the blood 
plasma and ocular tissues.  
Twelve adult NZW were used for histopathological and functional toxicity evaluation. The 
rabbits underwent 6 serial iontophoretic treatments (20min at 2.5mA) of either balanced salt 
solution (BSS) or carboplatin (14mg/ml) administered to the right eye at 72-hour intervals. 
The left eyes served as untreated controls. ERGs were recorded prior to the initial treatment, 
than at 48hrs after the 2nd treatment, and 4 weeks post final treatment. All eyes were examined 
clinically following each CCI application. 
Fifty-four 6 weeks old SV-40 transgenic mice underwent six, serial transcorneoscleral 
iontophoretic treatments (2.57mA/cm2, 5min) with carboplatin. Forty-four animals received 
carboplatin treatments at concentrations of 1.4, 7.0, 10.0, or 14mg/ml with or without current. 
Ten control mice underwent a treatment with balanced salt solution. Coulomb controlled 
iontophoresis treatment parameters include current density and charge application times were 
evaluated in 8 animals. Experimental and control eyes were examined for toxicity preceding 
each application. All eyes were obtained at 16 weeks of age for histopathological evaluation. 
Results: Determination of carboplatin concentrations via atomic absorption spectroscopy in 
the retina, choroid, vitreous humor, and optic nerve following subconjunctival injection and 
iontophoretic carboplatin delivery revealed significantly higher levels than those achieved 
with systemic administration. Peak levels of carboplatin in the retina were determined to be 
53.68ng/mg following subconjunctival, 38.0ng/mg post CCI-delivery and 14ng/mg after 
intravenous administration at 1hour post treatment. Concentrations in the vitreous humor 
following treatments peaked at differing times: 1hr post subconjunctival injection 
(4560ng/ml), 6hrs post CCI delivery (1955ng/ml) and 6hrs post intravenous delivery 
(1220ng/ml). Carboplatin concentrations in the blood plasma were found to be significantly 
higher following intravenous delivery with a concentration of 6222ng/ml at 1hour, compared 
to concentration of 182ng/ml and 261ng/ml at 1hour for subconjunctival and iontophoretic 
drug delivery.  
Light microscopy showed no histopathologic alterations in eyes treated with single or 
repetitive CCI carboplatin. ERGs revealed no depression in the a- or b-wave amplitude or 
alteration in the implicit times of the treated eyes. 
A dose–dependent inhibition of intraocular tumor was observed following repetitive 
iontophoretic treatment. None of the experimental eyes treated at carboplatin concentrations 
of 1.4mg/ml demonstrated complete tumor control. At concentrations of 7mg/ml the treated 
eyes exhibited tumor control of 50 %. All eyes treated with 14mg/ml showed complete tumor 
control. No corneal toxicity was observed in eyes treated at carboplatin concentrations less 
than 10mg/ml. At 14mg/ml all of the treated eyes revealed corneal damage. 
Conclusions: Focal administration of carboplatin utilizing subconjunctival or CCI, effectively 
transmits this chemotherapeutic drug into the target tissues of retina, choroid, vitreous and 
optic nerve. This data suggests local carboplatin delivery may be effective and well tolerated 
in the treatment of human retinoblastoma by increasing the intra-orbital carboplatin 
concentration while decreasing systemic exposure to this cytotoxic drug.  
Furthermore repetitive CCI administration demonstrated no signs of ocular toxicity and may 
present an alternative method to repetitive intravenous carboplatin administration. 
Transcorneoscleral Coulomb controlled iontophoretic delivery of carboplatin safely and 
effectively controls intraocular retinoblastoma in a dose dependent manner in this murine 
model of retinoblastoma. Topical non-invasive ocular iontophoretic administration of 
carboplatin chemotherapy may be advantageous in the treatment of intraocular pediatric 
retinoblastoma in comparison to systemically applied chemotherapy. 
 
